Firm Seeks License to Import Controlled Substances
Published Date: 6/15/2026
Notice
Summary
Cerilliant Corporation wants to become an official importer of certain controlled substances, including some drugs that need strict government oversight. People and companies involved with these substances can share their thoughts or ask for a hearing by July 15, 2026. This move could affect how these drugs enter the U.S. and might impact businesses handling them.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Cerilliant applied to import many controlled substances
On May 8, 2026, Cerilliant Corporation applied to be registered to import the long list of Schedule I and II controlled substances shown in the notice as bulk Active Pharmaceutical Ingredients to support making analytical reference standards and distributing them to research and forensic customers. Registered bulk manufacturers and applicants may submit comments or objections, or request a hearing, on or before July 15, 2026.
Import limited to bulk APIs; no finished dosage forms
The notice states that any registration, if approved, will authorize only importation of the listed substances as bulk Active Pharmaceutical Ingredients for analytical reference standards and distribution to research and forensic customers. Authorization will not extend to importing Food and Drug Administration–approved or non-approved finished dosage forms for commercial sale.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-19232, Esther Villanueva Valdes, M.D.; Decision and Order
Dr. Esther Villanueva Valdes from Puerto Rico lost her DEA registration because she’s no longer allowed to handle controlled substances and was excluded from federal health programs like Medicare and Medicaid. She didn’t ask for a hearing, so the decision to revoke her registration is final. This means she can’t legally prescribe or manage controlled drugs anymore, effective immediately.
2026-19231, Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
Starting October 21, 2026, diphenidine and its related forms will be officially listed as Schedule I drugs, meaning they’re considered highly controlled with no accepted medical use. This change affects anyone who makes, sells, studies, or even possesses diphenidine, bringing strict rules and serious penalties. The move helps the U.S. follow international drug laws and keep communities safer.
2026-18604, Joseph John Stubbers III, D.O.; Decision and Order
Dr. Joseph John Stubbers III from Ohio lost his DEA registration to handle controlled substances because he no longer has the legal authority to prescribe them in Ohio. He didn’t ask for a hearing to challenge this, so the DEA officially revoked his registration as of February 28, 2026. This means he can’t legally prescribe or manage controlled drugs anymore, impacting his medical practice and patients.
2026-18597, Craig Cohen, DPM; Decision and Order
Dr. Craig Cohen from Ohio lost his DEA registration because he no longer has permission to handle controlled substances in his state. He didn’t respond to the DEA’s attempts to contact him or request a hearing, so the agency revoked his certificate. This means he can’t legally prescribe or manage controlled drugs anymore, effective immediately.
Previous / Next Documents
Previous: 2026-11907, Certain TOPCon Solar Cells, Modules, Panels, Components Thereof, and Products Containing Same; Notice of a Commission Determination Not To Review an Initial Determination Granting Tesla, Inc.'s Motion To Intervene
Tesla just got the green light to join a big investigation about certain TOPCon solar products that might be breaking patent rules. This affects companies making or selling these solar cells and panels in the U.S., and it could shake up the solar market soon. Keep an eye out for updates because this could impact prices and who gets to sell these solar goodies.
Next: 2026-11910, Bulk Manufacturer of Controlled Substances Application: Veranova, L.P.
Veranova, L.P. wants to become a big-time maker of many controlled substances like fentanyl, marijuana, and methamphetamine. This means they’ll produce these drugs in large amounts to sell to customers and use in their own processes. People and companies can share their thoughts or ask for a hearing by August 14, 2026, so don’t miss the deadline!